Stocksigma LogoStocksigma Logo

Shree Ganesh Remedies Reports Q2 & H1FY27 Financial and Operational Performance

Shree Ganesh Remedies reported Q2FY27 revenue from operations of ₹23.29 crore, down 23% YoY but rebounding 62% QoQ

Shree Ganesh Remedies Reports Q2 & H1FY27 Financial and Operational Performance

Shree Ganesh Remedies Ltd · Investor Presentation · 02 Nov 2026, 12:38 am

Shree Ganesh Remedies Reports Q2 & H1FY27 Financial and Operational Performance Shree Ganesh Remedies reported Q2FY27 revenue from operations of ₹23.29 crore, down 23% YoY but rebounding 62% QoQ. Operating EBITDA declined 59% YoY to ₹3.94 crore with EBITDA margins contracting 1,483 bps YoY to 16.9%, impacted by subdued European demand and input cost volatility. PAT fell 67% YoY to ₹1.63 crore. For H1FY27, revenue stood at ₹37.65 crore (-32% YoY) and PAT at ₹2.75 crore (-67% YoY). Growth catalysts include commercializing two pharma intermediates, expanding CRAMS pipelines, completing Block 7A construction, and phased Dahej expansion.

Original exchange filing (PDF)

More announcements from Shree Ganesh Remedies Ltd

All Shree Ganesh Remedies Ltd announcements